A comparison of survival outcomes and side effects of toremifene or tamoxifen therapy in premenopausal estrogen and progesterone receptor positive breast cancer patients: a retrospective cohort study.
A comparison of survival outcomes and side effects of toremifene or tamoxifen therapy in premenopausal estrogen and progesterone receptor positive breast cancer patients: a retrospective cohort study.
复制标题
托瑞米芬或他莫昔芬治疗绝经前雌激素和孕激素受体阳性乳腺癌患者的生存结果和副作用的比较：一项回顾性队列研究
DOI：
10.1186/1471-2407-12-161
复制
发表时间：
2012-05-01
期刊：
影响因子：
3.8
通讯作者：
Su F
中科院分区：
文献类型：
--
作者：
Gu R;Jia W;Zeng Y;Rao N;Hu Y;Li S;Wu J;Jin L;Chen L;Long M;Chen K;Chen L;Xiao Q;Wu M;Song E;Su F
在绝经前妇女中，乳腺癌的内分泌辅助治疗主要由他莫昔芬单独或卵巢抑制策略组成。托瑞米芬是他莫昔芬的氯化衍生物，但风险-效益更佳。在这项回顾性研究中，我们试图确定托瑞米芬作为绝经前雌激素和/或孕激素受体阳性乳腺癌患者除他莫昔芬外的内分泌治疗的作用。从中山纪念医院（中国）乳腺肿瘤登记处选择早期浸润性乳腺癌患者。绝经前内分泌反应性乳腺癌患者接受标准治疗和托瑞米芬或他莫昔芬辅助治疗被认为是合格的。乳腺肉瘤、癌性肉瘤、并发对侧原发性乳腺癌、或诊断时有远处转移的患者，或未接受手术和内分泌治疗的患者均不适用。总生存期和无复发生存期是测量的主要结果。同时收集两组毒理资料进行比较。在810例患者中，452例患者被纳入研究分析：240例接受他莫昔芬治疗，212例接受托瑞米芬治疗。中位随访时间50.8个月，平均随访时间57.3个月。托瑞米芬和他莫昔芬的5年总生存率相近，分别为100%和98.4% （p = 0.087）。然而，托瑞米芬组的无复发生存率明显优于他莫昔芬组（p = 0.022）。多因素分析显示，托瑞米芬独立改善无复发生存率（HR = 0.385, 95% CI = 0.154-0.961; p = 0.041）。两个治疗组的毒性相似，除了在托瑞米芬组患者中更常见的潮热以外，没有妇女出现严重的并发症（p = 0.049）。没有患者发生子宫内膜癌。对于绝经前患有内分泌反应性乳腺癌的妇女，托雷米芬可能是一种有效和安全的他莫西芬替代品。
In premenopausal women, endocrine adjuvant therapy for breast cancer primarily consists of tamoxifen alone or with ovarian suppressive strategies. Toremifene is a chlorinated derivative of tamoxifen, but with a superior risk-benefit profile. In this retrospective study, we sought to establish the role of toremifene as an endocrine therapy for premenopausal patients with estrogen and/or progesterone receptor positive breast cancer besides tamoxifen. Patients with early invasive breast cancer were selected from the breast tumor registries at the Sun Yat-Sen Memorial Hospital (China). Premenopausal patients with endocrine responsive breast cancer who underwent standard therapy and adjuvant therapy with toremifene or tamoxifen were considered eligible. Patients with breast sarcoma, carcinosarcoma, concurrent contralateral primary breast cancer, or with distant metastases at diagnosis, or those who had not undergone surgery and endocrine therapy were ineligible. Overall survival and recurrence-free survival were the primary outcomes measured. Toxicity data was also collected and compared between the two groups. Of the 810 patients reviewed, 452 patients were analyzed in the study: 240 received tamoxifen and 212 received toremifene. The median and mean follow up times were 50.8 and 57.3 months, respectively. Toremifene and tamoxifen yielded similar overall survival values, with 5-year overall survival rates of 100% and 98.4%, respectively (p = 0.087). However, recurrence-free survival was significantly better in the toremifene group than in the tamoxifen group (p = 0.022). Multivariate analysis showed that recurrence-free survival improved independently with toremifene (HR = 0.385, 95% CI = 0.154-0.961; p = 0.041). Toxicity was similar in the two treatment groups with no women experiencing severe complications, other than hot flashes, which was more frequent in the toremifene patients (p = 0.049). No patients developed endometrial cancer. Toremifene may be a valid and safe alternative to tamoxifen in premenopausal women with endocrine-responsive breast cancer.
登录
查看更多内容
影响因子：
45.3
作者：
Holli, K;Valavaara, R;Joensuu, H
通讯作者：
Joensuu, H
影响因子：
3.2
作者：
Cummings, FJ
通讯作者：
Cummings, FJ
影响因子：
7.3
作者：
Kuramochi, H
通讯作者：
Kuramochi, H
影响因子：
45.3
作者：
FORNANDER, T;RUTQVIST, LE;GLAS, U
通讯作者：
GLAS, U
DOI：
10.1046/j.1524-4741.2002.08204.x
发表时间：
2002-03-01
期刊：
The breast journal
影响因子：
--
作者：
Hirsimaki, Pirkko;Aaltonen, Annukka;Mantyla, Eero
通讯作者：
Mantyla, Eero